PA-12-149: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp): Metabolomic biomarkers and instrumentation for assessment of radiation injury,

PA-12-149：促进健康相关研究多样性的研究补充（管理补充）：用于评估辐射损伤的代谢组生物标志物和仪器，

• 批准号: 8991790
• 负责人: Albert J Fornace
• 金额: $ 6.02万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-24 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8991790
• 关键词: Age; Algorithms; Animal Model; Bioinformatics; Biological Markers; Blood; Burn Trauma; Cells; Clinical; Collection; Data; Data Set; Databases; Detection; Development; Disease; Dose; Dose-Limiting; Exposure to; Filtration; Funding; Gender; Goals; Health; House mice; Housing; Human; Human Volunteers; In Vitro; Inflammatory; Inflammatory Response; Injury; Ionizing radiation; Ions; Laboratories; Lipopolysaccharides; Liquid Chromatography; Lung; Mass Spectrum Analysis; Measures; Metabolic; Methods; Modeling; Monitor; Mus; National Institute of Allergy and Infectious Disease; Neutrons; Organ; Outcome; Paper; Patients; Preparation; Process; Protocols documentation; Publications; Publishing; Radiation; Radiation Injuries; Radiation Toxicity; Reporting; Research; Sampling; Seminal; Sepsis; Series; Serum; Severities; Signal Transduction; Small Intestines; Specificity; Spectrometry; Stress; System; Text; Time; Toxic effect; Urine; Validation; Whole-Body Irradiation; base; biological adaptation to stress; biomarker development; biomarker discovery; biomarker panel; cohort; cost effective; experience; exposed human population; in vivo; insight; instrument; instrumentation; interest; ionization technique; irradiation; liquid chromatography mass spectrometry; member; metabolomics; mouse model; nonhuman primate; novel; radiation response; response; small molecule; stressor

DESCRIPTION (provided by applicant): This proposal combines our metabolomics and radiation-signaling expertise with the expertise of team members in instrumentation for rapid and cost-effective assessment of select metabolites. The overall goals are to develop a reliable database of radiation metabolomic biomarkers in humans from easily-accessible biofluids, and then to refine subset(s) that will allow assessment of select biomarkers with instrumentation that could provide the basis for application in clinical and potentially in-field scenarios. The propose study builds on an extensive track record of accomplishments in radiation metabolomics, as well as the use of approaches, particularly differential mobility spectrometry (DMS), that allows for high-throughput assessment of metabolite biomarkers of interest. In the case of radiation metabolomics, our laboratory and its collaborators have made major contributions in establishing this field using a modern liquid chromatography (LC) mass spectrometry (MS) approach in a variety of animal models as well as in human cells. We have shown in publications over the last several years that they are dose-dependent and timecourse-dependent responses in urine metabolomics profiles after doses of ionizing radiation (IR) that are a NIAID priority. Recently, we have shown that there is evidence for specificity in the IR response in vivo compared to another relevant stressor, which mimics the inflammatory response to sepsis. Our team has also published extensively on the development and refinement of DMS, which should allow for selective "tuning" for metabolite biomarkers without cumbersome LC. We have demonstrated that DMS allows isolation of select metabolites so that they can then be detected with a simplified and miniature MS system. In the case of human biomarker development, we have a collection of biofluids from a large number of patients undergoing total body irradiation (TBI) and have already demonstrated significant metabolomic responses in urine after TBI. Aim 1 will be to develop a robust metabolomic biomarker database for human exposure using our high-end laboratory LCMS approach. Since dose and timecourse sampling is limited in TBI patients, we will use our extensive on-going mouse model datasets, which are funded by a different mechanism, as well as non-human primate samples provided by collaborators to model a much wider range of exposures. In the case of radiation toxicity, we have exciting preliminary data demonstrating that toxicity and lethality, which occurs approximately 2 wk after irradiation, can be distinguished as early as 1 day after irradiation in mice. Aim 2 will develop biomarker panels to distinguish IR biomarker signatures from other injury and disease processes. A modern bioinformatics pipeline, which includes novel in-house algorithms, has been developed to facilitate biomarker discovery. Having developed a robust IR dataset, we will then focus in aim 3 on development of convenient and cost-effective instrumentation that can provide the basis for use in clinical and ultimately in-field scenarios, and refine subsets of IR biomarkers that can be effectively measured with our approaches such as DMS-MS.

描述（由申请人提供）：该提案将我们的代谢组学和辐射信号专业知识与团队成员在仪器方面的专业知识相结合，以快速且经济有效地评估选定的代谢物。总体目标是从易于获取的生物流体中开发人类辐射代谢组生物标志物的可靠数据库，然后细化子集，以便使用仪器评估选定的生物标志物，从而为临床应用和潜在的应用提供基础。 - 现场场景。该拟议研究建立在辐射代谢组学方面的广泛成就记录以及方法的使用基础上，特别是差分迁移光谱法（DMS），可以对感兴趣的代谢物生物标志物进行高通量评估。就辐射代谢组学而言，我们的实验室及其合作者在各种动物模型以及人类细胞中使用现代液相色谱 (LC) 质谱 (MS) 方法为建立这一领域做出了重大贡献。我们在过去几年的出版物中表明，在接受 NIAID 优先考虑的电离辐射 (IR) 剂量后，尿液代谢组学谱中的反应呈剂量依赖性和时间依赖性。最近，我们已经证明，有证据表明与另一种相关应激源相比，体内 IR 反应具有特异性，该应激源模拟脓毒症的炎症反应。我们的团队还广泛发表了有关 DMS 的开发和完善的文章，这应该允许对代谢生物标志物进行选择性“调整”，而无需繁琐的 LC。我们已经证明，DMS 可以分离选定的代谢物，以便可以使用简化的微型 MS 系统检测它们。在人类生物标志物开发方面，我们收集了大量接受全身照射 (TBI) 的患者的生物体液，并且已经在 TBI 后的尿液中证明了显着的代谢组反应。目标 1 是使用我们的高端实验室 LCMS 方法开发一个强大的人类暴露代谢组生物标志物数据库。由于 TBI 患者的剂量和时间过程采样有限，我们将使用我们广泛的持续小鼠模型数据集（这些数据集由不同的机制资助）以及合作者提供的非人类灵长类动物样本来模拟更广泛的暴露范围。就辐射毒性而言，我们有令人兴奋的初步数据表明，在小鼠中，辐射后约 2 周发生的毒性和致死性最早可在辐射后 1 天区分。目标 2 将开发生物标志物组，以区分 IR 生物标志物特征与其他损伤和疾病过程。现代生物信息学管道（包括新颖的内部算法）已经开发出来，以促进生物标志物的发现。开发出强大的 IR 数据集后，我们将重点关注目标 3：开发方便且具有成本效益的仪器，为临床和最终现场场景的使用提供基础，并完善可有效测量的 IR 生物标志物子集使用我们的方法，例如 DMS-MS。